US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
US6057287A
(en)
|
1994-01-11 |
2000-05-02 |
Dyax Corp. |
Kallikrein-binding "Kunitz domain" proteins and analogues thereof
|
US7270809B2
(en)
*
|
1997-07-14 |
2007-09-18 |
Bolder Biotechnology, Inc. |
Cysteine variants of alpha interferon-2
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
CA2296770A1
(en)
*
|
1997-07-14 |
1999-01-28 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
CA2343094A1
(en)
|
1998-10-16 |
2000-04-27 |
Biogen, Inc. |
Interferon-beta fusion proteins and uses
|
EE05201B1
(et)
|
1998-10-16 |
2009-08-17 |
Biogen Idec Ma Inc. |
Glkoslitud interferoon-beeta, selle kasutamine ja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
CO5160259A1
(es)
*
|
1999-03-02 |
2002-05-30 |
Schering Corp |
Interferon alfa pegilado en la terapia contra el hiv
|
US6605273B2
(en)
|
1999-04-08 |
2003-08-12 |
Schering Corporation |
Renal cell carcinoma treatment
|
US6923966B2
(en)
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
US6362162B1
(en)
|
1999-04-08 |
2002-03-26 |
Schering Corporation |
CML Therapy
|
US6849254B1
(en)
|
1999-04-19 |
2005-02-01 |
Schering Corporation |
HCV combination therapy
|
US6969524B1
(en)
|
1999-10-12 |
2005-11-29 |
Santen Pharamceutical Co., Ltd. |
Interferon complex and medicinal use thereof
|
US7230081B1
(en)
|
1999-11-12 |
2007-06-12 |
Maxygen Holdings, Ltd. |
Interferon gamma conjugates
|
EP1231943A1
(en)
*
|
1999-11-12 |
2002-08-21 |
Maxygen Holdings Ltd |
Interferon gamma conjugates
|
ATE435033T1
(de)
|
2000-01-10 |
2009-07-15 |
Maxygen Holdings Ltd |
G-csf konjugate
|
EP2319541A1
(en)
|
2000-02-11 |
2011-05-11 |
Bayer HealthCare LLC |
Factor VII or VIIA-like conjugates
|
AU2001249120A1
(en)
*
|
2000-03-09 |
2001-09-17 |
Schering Corporation |
Hiv immune adjuvant therapy
|
KR100353392B1
(ko)
*
|
2000-03-13 |
2002-09-18 |
선바이오(주) |
높은 생체 활성도를 갖는 생체 활성 단백질과 peg의결합체 제조방법
|
US6476062B2
(en)
|
2000-03-30 |
2002-11-05 |
Schering Corporation |
Chemokine receptor antagonists
|
ES2256234T3
(es)
*
|
2000-05-16 |
2006-07-16 |
Lipoxen Technologies Limited |
Derivatizacion de proteinas en solucion acuosa.
|
US20040067527A1
(en)
*
|
2000-07-26 |
2004-04-08 |
Sara Lavi |
Intracellular delivery system for protein phosphatases and other polypeptides
|
US7208167B2
(en)
*
|
2000-08-07 |
2007-04-24 |
Sciclone Pharmaceuticals, Inc. |
Treatment of hepatitis C with thymosin and peptide combination therapy
|
US7118737B2
(en)
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
JP2004518621A
(ja)
*
|
2000-09-08 |
2004-06-24 |
グリフォン セラピューティクス,インコーポレーテッド |
「擬似」天然型化学的ライゲーション
|
ES2367891T3
(es)
*
|
2000-09-29 |
2011-11-10 |
Schering Corporation |
Interleucina-10 pegilada.
|
US7060675B2
(en)
*
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
US6867183B2
(en)
*
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
EP1366075B1
(en)
|
2001-02-27 |
2009-05-27 |
Maxygen Aps |
New interferon beta-like molecules
|
US6958388B2
(en)
|
2001-04-06 |
2005-10-25 |
Maxygen, Aps |
Interferon gamma polypeptide variants
|
US7038015B2
(en)
*
|
2001-04-06 |
2006-05-02 |
Maxygen Holdings, Ltd. |
Interferon gamma polypeptide variants
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
*
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828297B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6835802B2
(en)
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6858580B2
(en)
*
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7196059B2
(en)
*
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
WO2003037915A1
(en)
*
|
2001-10-31 |
2003-05-08 |
Biopolymed Inc. |
Biocompatible polymers including peptide spacer
|
KR100480429B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
|
KR100480430B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
인터페론-베타와 폴리에틸렌글리콜 유도체의 배합체
|
WO2003049760A1
(en)
*
|
2001-12-07 |
2003-06-19 |
Intermune, Inc. |
Compositions and method for treating hepatitis virus infection
|
CN1630530A
(zh)
|
2002-01-18 |
2005-06-22 |
比奥根艾迪克Ma公司 |
聚亚烷基聚合物及其用途
|
EP1490402A4
(en)
*
|
2002-03-20 |
2007-05-02 |
Biopolymed Inc |
PREPARATION OF CYSTEINREST STOCHIOMETRIC WITH BIOKOMPATIBLE POLYMER CONJUGATED G-CSF
|
ES2528254T3
(es)
|
2002-06-07 |
2015-02-05 |
Dyax Corp. |
Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico
|
US7153829B2
(en)
|
2002-06-07 |
2006-12-26 |
Dyax Corp. |
Kallikrein-inhibitor therapies
|
UA86744C2
(en)
|
2002-06-21 |
2009-05-25 |
Ново Нордиск Хэлс Кеа Аг |
Pegylated factor vii glycoforms
|
CN104193791A
(zh)
|
2002-06-28 |
2014-12-10 |
埃迪尼克斯医药公司 |
用于治疗黄病毒感染的修饰的2’和3’-核苷前药
|
US7524931B2
(en)
*
|
2002-07-03 |
2009-04-28 |
Maxygen Holdings Ltd. |
Full-length interferon gamma polypeptide variants
|
ES2395014T3
(es)
*
|
2002-08-28 |
2013-02-07 |
Dyax Corp. |
Métodos para conservar órganos y tejidos
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US20040062748A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
CN1323722C
(zh)
*
|
2002-11-15 |
2007-07-04 |
霍夫曼-拉罗奇有限公司 |
PEG干扰素α-2a的位置异构体
|
EP1667708B9
(en)
|
2002-12-26 |
2012-10-31 |
Mountain View Pharmaceuticals, Inc. |
POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY
|
BR0317752A
(pt)
*
|
2002-12-26 |
2005-11-22 |
Mountain View Pharmaceuticals |
Conjugados poliméricos de citocinas, quimiocinas, fatores do crescimento, hormÈnios polipeptìdicos e seus antagonistas com atividade de ligação a receptores conservada
|
WO2004084949A2
(en)
*
|
2003-03-20 |
2004-10-07 |
Xencor |
Generating protein pro-drugs using reversible ppg linkages
|
JP2006521372A
(ja)
*
|
2003-03-28 |
2006-09-21 |
バイオポリメド インコーポレーテッド |
生物学的活性物質と生体適合性高分子の1:1接合体、この製造方法とこれを含む薬学組成物
|
US20050281778A1
(en)
*
|
2003-03-28 |
2005-12-22 |
Myung-Ok Park |
Human growth hormone conjugated with biocompatible polymer
|
US20060134736A1
(en)
*
|
2003-03-28 |
2006-06-22 |
Jacobs John W |
Human growth hormone conjugated with biocompatible polymer
|
DE602004025799D1
(de)
|
2003-04-15 |
2010-04-15 |
Glaxosmithkline Llc |
Humane il-18 substitutionsmutanten und deren konjugate
|
EP1633317A4
(en)
|
2003-05-16 |
2008-08-20 |
Intermune Inc |
Synthetic chemokine receptor ligands and methods of use therefor
|
US7429572B2
(en)
|
2003-05-30 |
2008-09-30 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
CA2534995A1
(en)
*
|
2003-07-31 |
2005-05-19 |
Anticancer, Inc. |
The use of plp with peg-rmetase in vivo for enhanced efficacy
|
CN102516386A
(zh)
|
2003-10-10 |
2012-06-27 |
诺沃挪第克公司 |
Il-21衍生物
|
RS20110578A3
(en)
|
2003-10-14 |
2016-02-29 |
F. Hoffmann-La Roche Ltd |
MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
|
EP2633866A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
US20050089952A1
(en)
*
|
2003-10-22 |
2005-04-28 |
Akzo Nobel N.V. |
Apparatuses and processes for increasing protein PEGylation reaction yields
|
WO2005040758A2
(en)
*
|
2003-10-24 |
2005-05-06 |
Intermune, Inc. |
Use of pirfenidone in therapeutic regimens
|
US20070258946A1
(en)
*
|
2003-12-23 |
2007-11-08 |
Blatt Lawrence M |
Combination Therapy for Treating Hepatitis C Virus Infection
|
US7608663B2
(en)
*
|
2004-01-21 |
2009-10-27 |
Nektar Therapeutics |
Method of preparing propionic acid-terminated polymers
|
BRPI0507169A
(pt)
|
2004-02-02 |
2007-06-26 |
Ambrx Inc |
polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
|
US20090214472A1
(en)
*
|
2004-03-01 |
2009-08-27 |
Enzon Pharmaceuticals Inc. |
Interferon-beta polymer conjugates
|
CN1984924B
(zh)
|
2004-03-17 |
2011-08-10 |
抗癌公司 |
提高蛋白质与聚乙二醇(peg)结合度的方法
|
EP1586334A1
(en)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF conjugates with peg
|
US20060018875A1
(en)
*
|
2004-06-14 |
2006-01-26 |
Blatt Lawrence M |
Interferon compositions and methods of use thereof
|
US20050281872A1
(en)
*
|
2004-06-16 |
2005-12-22 |
Peter Summerville |
Enhanced compliance antiviral medicaments and methods of manufacture and use
|
KR20070034512A
(ko)
|
2004-06-18 |
2007-03-28 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
US7605123B2
(en)
|
2004-07-19 |
2009-10-20 |
Biocon Ltd. |
Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof
|
JP2008515774A
(ja)
|
2004-08-03 |
2008-05-15 |
ダイアックス コーポレイション |
hK1結合タンパク質
|
BRPI0513332A
(pt)
*
|
2004-08-12 |
2008-05-06 |
Schering Corp |
formulação de interferon peguilado estável
|
SI3109244T1
(sl)
|
2004-09-14 |
2019-06-28 |
Gilead Pharmasset Llc |
Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov
|
US7235530B2
(en)
|
2004-09-27 |
2007-06-26 |
Dyax Corporation |
Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
|
CA2594561C
(en)
|
2004-12-22 |
2014-12-23 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
WO2006068802A2
(en)
|
2004-12-22 |
2006-06-29 |
Ambrx, Inc. |
COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
|
AU2005323106B2
(en)
|
2004-12-22 |
2010-07-29 |
Ambrx, Inc. |
Methods for expression and purification of recombinant human growth hormone
|
CA2594557C
(en)
|
2004-12-22 |
2016-04-26 |
Ambrx, Inc. |
Modified human growth hormone
|
US7365127B2
(en)
*
|
2005-02-04 |
2008-04-29 |
Enzon Pharmaceuticals, Inc. |
Process for the preparation of polymer conjugates
|
KR20140068234A
(ko)
|
2005-03-31 |
2014-06-05 |
더 제너럴 하스피탈 코포레이션 |
Hgf/hgfr 활성의 모니터링 및 조정
|
WO2006133089A2
(en)
|
2005-06-03 |
2006-12-14 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
WO2006134173A2
(en)
|
2005-06-17 |
2006-12-21 |
Novo Nordisk Health Care Ag |
Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
|
AU2006278490A1
(en)
*
|
2005-08-04 |
2007-02-15 |
Nektar Therapeutics |
Conjugates of a G-CSF moiety and a polymer
|
PL2407486T3
(pl)
|
2005-08-19 |
2018-05-30 |
Wyeth Llc |
Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
|
CN101454461A
(zh)
|
2005-11-16 |
2009-06-10 |
Ambrx公司 |
包括非天然氨基酸的方法和组合物
|
CU23556A1
(es)
*
|
2005-11-30 |
2010-07-20 |
Ct Ingenieria Genetica Biotech |
Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
|
WO2007080942A1
(ja)
|
2006-01-12 |
2007-07-19 |
The Kitasato Institute |
インターフェロンαを含む口腔組成物
|
ITMI20060612A1
(it)
*
|
2006-03-30 |
2007-09-30 |
Keryos Spa |
New activaded poly-ethylene glycols-and related polymers and their applications
|
EP2001502A1
(en)
*
|
2006-03-31 |
2008-12-17 |
Schering Corporation |
Parenteral low dose type 1 interferons for bladder cancer
|
JP5313129B2
(ja)
|
2006-05-02 |
2013-10-09 |
アロザイン, インコーポレイテッド |
非天然アミノ酸置換ポリペプチド
|
US20080096819A1
(en)
*
|
2006-05-02 |
2008-04-24 |
Allozyne, Inc. |
Amino acid substituted molecules
|
EP2213733A3
(en)
|
2006-05-24 |
2010-12-29 |
Novo Nordisk Health Care AG |
Factor IX analogues having prolonged in vivo half life
|
US20070282170A1
(en)
*
|
2006-05-30 |
2007-12-06 |
Sundaram Ravikumar |
Rake Retractor and Needle Assembly for Minimally Invasive Surgical Applications
|
US8008948B2
(en)
*
|
2006-07-06 |
2011-08-30 |
Denso Corporation |
Peak voltage detector circuit and binarizing circuit including the same circuit
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
JP2010510171A
(ja)
*
|
2006-08-21 |
2010-04-02 |
ユナイテッド セラピューティクス コーポレーション |
ウイルス感染症の治療のための併用療法
|
JP5451390B2
(ja)
|
2006-09-08 |
2014-03-26 |
アンブルックス,インコーポレイテッド |
脊椎動物細胞内におけるサプレッサーtrnaの転写
|
CN106008699A
(zh)
|
2006-09-08 |
2016-10-12 |
Ambrx公司 |
经修饰的人类血浆多肽或Fc骨架和其用途
|
ATE487497T1
(de)
*
|
2006-09-29 |
2010-11-15 |
Canji Inc |
Verfahren und zusammensetzungen für gentherapie
|
US8679472B1
(en)
|
2006-10-05 |
2014-03-25 |
Merck, Sharp & Dohme Corp. |
Crystal of human interferon alpha 2B in complex with zinc
|
KR101079993B1
(ko)
*
|
2006-11-17 |
2011-11-04 |
동아제약주식회사 |
폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
|
DK2097068T3
(da)
|
2006-11-24 |
2013-10-28 |
Cadila Healthcare Ltd |
Formuleringer af peg-interferon-alpha-konjugater
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
KR101476472B1
(ko)
|
2007-03-30 |
2015-01-05 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
MX2009011870A
(es)
|
2007-05-02 |
2009-11-12 |
Ambrx Inc |
Polipeptidos de interferon beta modificados y usos de los mismos.
|
CN101361968B
(zh)
|
2007-08-06 |
2011-08-03 |
健能隆医药技术(上海)有限公司 |
白介素-22在治疗脂肪肝中的应用
|
CL2008002399A1
(es)
*
|
2007-08-16 |
2009-01-02 |
Pharmaessentia Corp |
Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
|
CA2707840A1
(en)
*
|
2007-08-20 |
2009-02-26 |
Allozyne, Inc. |
Amino acid substituted molecules
|
CA2698173C
(en)
*
|
2007-09-04 |
2015-02-03 |
Biosteed Gene Expression Tech. Co., Ltd. |
Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof
|
PL2196475T3
(pl)
*
|
2007-09-04 |
2012-10-31 |
Biosteed Gene Expression Tech Co Ltd |
Interferon alfa 2a zmodyfikowany rozgałęzioną cząsteczką glikolu polietylenowego, sposób jego syntezy i zastosowanie
|
JP5868594B2
(ja)
*
|
2007-10-16 |
2016-02-24 |
バイオコン・リミテッドBiocon Limited |
経口投与可能な固形医薬組成物及びそのプロセス
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
ES2632504T3
(es)
|
2007-11-20 |
2017-09-13 |
Ambrx, Inc. |
Polipéptidos de insulina modificados y sus usos
|
NZ602170A
(en)
|
2008-02-08 |
2014-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
JP5675606B2
(ja)
|
2008-07-08 |
2015-02-25 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
シグナル伝達性転写因子(stat)の増殖及び活性化の新規の抑制剤
|
JP5680534B2
(ja)
|
2008-07-23 |
2015-03-04 |
イーライ リリー アンド カンパニー |
修飾されているウシg−csfポリペプチドおよびそれらの使用
|
MX2011001167A
(es)
*
|
2008-07-31 |
2011-04-12 |
Pharmaessentia Corp |
Conjugados peptido-polimero.
|
EP2344201A1
(en)
*
|
2008-09-17 |
2011-07-20 |
Nektar Therapeutics |
Oligomer-protease inhibitor conjugates
|
ES2660000T3
(es)
|
2008-09-26 |
2018-03-20 |
Ambrx, Inc. |
Vacunas y microorganismos dependientes de la replicación de aminoácidos no naturales
|
MX2011003272A
(es)
|
2008-09-26 |
2011-04-28 |
Ambrx Inc |
Polipeptidos de eritropoyetina animal modificados y sus usos.
|
EP3025727A1
(en)
|
2008-10-02 |
2016-06-01 |
The J. David Gladstone Institutes |
Methods of treating liver disease
|
RU2549702C2
(ru)
|
2008-12-17 |
2015-04-27 |
Мерк Шарп И Доум Корп., |
Получение и применение моно- и ди-пэг il-10
|
EA019341B1
(ru)
|
2008-12-23 |
2014-02-28 |
Джилид Фармассет, Ллс. |
Фосфорамидаты нуклеозидов
|
PA8855701A1
(es)
|
2008-12-23 |
2010-07-27 |
|
Análogos de nucleósidos
|
WO2010075554A1
(en)
|
2008-12-23 |
2010-07-01 |
Pharmasset, Inc. |
Synthesis of purine nucleosides
|
JP2012520884A
(ja)
|
2009-03-18 |
2012-09-10 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー |
フラビウイルス科ウイルス感染症を治療する方法および組成物
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
JP2013515080A
(ja)
|
2009-12-21 |
2013-05-02 |
アンブルックス,インコーポレイテッド |
修飾されているウシのソマトトロピンポリペプチドおよびそれらの使用
|
EP2805965A1
(en)
|
2009-12-21 |
2014-11-26 |
Ambrx, Inc. |
Modified porcine somatotropin polypeptides and their uses
|
PT3459564T
(pt)
*
|
2010-01-06 |
2022-01-31 |
Takeda Pharmaceuticals Co |
Proteínas de ligação à calicreína plasmática
|
EP2542569B1
(en)
|
2010-03-05 |
2020-09-16 |
Omeros Corporation |
Chimeric inhibitor molecules of complement activation
|
BR112012024884A2
(pt)
|
2010-03-31 |
2016-10-18 |
Gilead Pharmasset Llc |
síntese estereosseletiva de ativos contendo fósforo
|
EP2569331A1
(en)
|
2010-05-10 |
2013-03-20 |
Perseid Therapeutics LLC |
Polypeptide inhibitors of vla4
|
RU2447083C1
(ru)
*
|
2010-07-20 |
2012-04-10 |
Закрытое Акционерное Общество "Биокад" |
НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
ES2972902T3
(es)
|
2010-08-17 |
2024-06-17 |
Ambrx Inc |
Polipéptidos de relaxina modificados y sus usos
|
CN102380091A
(zh)
|
2010-08-31 |
2012-03-21 |
健能隆医药技术(上海)有限公司 |
白介素-22在治疗病毒性肝炎中的应用
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
EP2646453A1
(en)
|
2010-11-30 |
2013-10-09 |
Gilead Pharmasset LLC |
Compounds
|
KR102107695B1
(ko)
|
2011-01-06 |
2020-05-07 |
다이액스 코포레이션 |
혈장 칼리크레인 결합 단백질
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
KR20140054009A
(ko)
|
2011-07-01 |
2014-05-08 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
릴랙신 융합 폴리펩타이드 및 그의 용도
|
EP2734640A1
(en)
|
2011-07-20 |
2014-05-28 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods for determining treatment response in patients infected with hcv genotype 4
|
WO2013024158A1
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
|
WO2013024156A2
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
US9364484B2
(en)
|
2011-12-06 |
2016-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for treating viral diseases
|
WO2013174988A1
(en)
|
2012-05-24 |
2013-11-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and monitoring treatment response in hcv- and hcv/hiv-infected subjects
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
NZ702269A
(en)
|
2012-06-15 |
2017-07-28 |
Pfizer |
Improved antagonist antibodies against gdf-8 and uses therefor
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
WO2014033266A1
(en)
|
2012-08-31 |
2014-03-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
|
SG11201501464TA
(en)
|
2012-08-31 |
2015-03-30 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
EA021610B1
(ru)
*
|
2013-03-28 |
2015-07-30 |
Илья Александрович МАРКОВ |
Жидкое противовирусное лекарственное средство
|
EA023360B1
(ru)
*
|
2013-03-28 |
2016-05-31 |
Илья Александрович МАРКОВ |
Линейный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
|
EA021643B1
(ru)
*
|
2013-03-28 |
2015-07-30 |
Илья Александрович МАРКОВ |
Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
|
CN105209054A
(zh)
|
2013-04-18 |
2015-12-30 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素-10治疗疾病和病症的方法
|
ES2688206T3
(es)
|
2013-06-17 |
2018-10-31 |
Armo Biosciences, Inc. |
Procedimiento de evaluación de la identidad y la estabilidad de proteínas
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
PT3650014T
(pt)
|
2013-08-27 |
2021-12-27 |
Gilead Pharmasset Llc |
Formulação combinada de dois compostos antivirais
|
CN105658232A
(zh)
|
2013-08-30 |
2016-06-08 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素-10治疗疾病和病症的方法
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
CN104623637A
(zh)
|
2013-11-07 |
2015-05-20 |
健能隆医药技术(上海)有限公司 |
Il-22二聚体在制备静脉注射药物中的应用
|
MX2016005915A
(es)
|
2013-11-11 |
2016-12-16 |
Armo Biosciences Inc |
Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
|
JP6719384B2
(ja)
|
2014-03-27 |
2020-07-15 |
ダイアックス コーポレーション |
糖尿病黄斑浮腫の治療のための組成物および方法
|
CN111265525A
(zh)
|
2014-05-01 |
2020-06-12 |
艾格尔峰生物制药有限公司 |
丁型肝炎病毒感染的治疗
|
US11311519B2
(en)
|
2014-05-01 |
2022-04-26 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
US10076512B2
(en)
|
2014-05-01 |
2018-09-18 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
RU2554761C1
(ru)
*
|
2014-05-13 |
2015-06-27 |
Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" |
Противоэнтеровирусное и иммуностимулирующее средство
|
CN106573072A
(zh)
|
2014-06-02 |
2017-04-19 |
阿尔莫生物科技股份有限公司 |
降低血清胆固醇的方法
|
KR101736870B1
(ko)
*
|
2014-08-20 |
2017-05-18 |
한국코러스 주식회사 |
인터페론 접합체를 포함하는 복합체 및 이의 제조방법
|
US10350270B2
(en)
|
2014-10-14 |
2019-07-16 |
Armo Biosciences, Inc. |
Interleukin-15 compositions and uses thereof
|
MX2017004983A
(es)
|
2014-10-22 |
2017-11-13 |
Armo Biosciences Inc |
Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
|
AU2015335603B2
(en)
|
2014-10-24 |
2020-04-30 |
Bristol-Myers Squibb Company |
Modified FGF-21 polypeptides and uses thereof
|
CA2964390A1
(en)
|
2014-11-06 |
2016-05-12 |
Pharmaessentia Corporation |
Dosage regimen for pegylated interferon
|
WO2016126615A1
(en)
|
2015-02-03 |
2016-08-11 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
EP3285768B1
(en)
|
2015-04-21 |
2020-12-30 |
Eiger Biopharmaceuticals, Inc. |
Pharmaceutical compositions comprising lonafarnib and ritonavir
|
AU2016268403A1
(en)
|
2015-05-28 |
2017-12-07 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
CN108025040A
(zh)
|
2015-08-25 |
2018-05-11 |
阿尔莫生物科技股份有限公司 |
使用白介素-10治疗疾病和病症的方法
|
EP3858352A1
(en)
|
2015-11-04 |
2021-08-04 |
Eiger Biopharmaceuticals, Inc. |
Treatment of hepatitis delta virus infection
|
US11286307B2
(en)
|
2015-12-11 |
2022-03-29 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
|
US11510966B2
(en)
|
2016-04-15 |
2022-11-29 |
Evive Biotechnology (Shanghai) Ltd |
Use of IL-22 in treating necrotizing enterocolitis
|
CN106539557A
(zh)
*
|
2016-10-08 |
2017-03-29 |
西安交通大学 |
一种基于恒速静脉输入的药代动力学参数的测定方法
|
KR20220147720A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
JP7189399B2
(ja)
|
2017-01-18 |
2022-12-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物
|
AU2018219283B2
(en)
|
2017-02-08 |
2022-05-19 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
WO2019020593A1
(en)
|
2017-07-25 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
|
RU2678332C1
(ru)
|
2017-09-08 |
2019-01-28 |
Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") |
Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
|
SI3849614T1
(sl)
|
2018-09-11 |
2024-04-30 |
Ambrx, Inc. |
Polipeptidni konjugati interlevkina-2 in njihove uporabe
|
CN113366015A
(zh)
|
2018-10-19 |
2021-09-07 |
Ambrx公司 |
白细胞介素-10多肽缀合物、其二聚体及其用途
|
KR20210136014A
(ko)
|
2019-02-12 |
2021-11-16 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도
|
EP3999101A1
(en)
|
2019-07-18 |
2022-05-25 |
ENYO Pharma |
Method for decreasing adverse-effects of interferon
|
WO2021178612A1
(en)
|
2020-03-05 |
2021-09-10 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
IL296099A
(en)
|
2020-03-11 |
2022-11-01 |
Ambrx Inc |
Interleukin-2 polypeptide conjugates and methods of using them
|
WO2021228983A1
(en)
|
2020-05-13 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
|
EP3912627B1
(en)
|
2020-05-20 |
2022-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of coronavirus infections
|
WO2021263271A1
(en)
|
2020-06-22 |
2021-12-30 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis d virus infection
|
EP3954393A1
(en)
|
2020-08-13 |
2022-02-16 |
Bioasis Technologies Inc. |
Combination therapies for delivery across the blood brain barrier
|
US20230302150A1
(en)
|
2020-08-20 |
2023-09-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
WO2022043496A2
(en)
|
2020-08-28 |
2022-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of mait cells as biomarkers and biotargets in covid-19
|
WO2022079205A1
(en)
|
2020-10-15 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of ifn-alpha polypeptides for the treatment of coronavirus infections
|
EP4313163A1
(en)
|
2021-04-03 |
2024-02-07 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|